- Home
- XERS vs MSEX Comparison
XERS vs MSEX Comparison
Compare XERS & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | MSEX |
|---|---|---|
| Founded | 2005 | 1897 |
| Country | United States | United States |
| Employees | N/A | 395 |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | XERS | MSEX |
|---|---|---|
| Price | $6.18 | $52.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $10.83 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 1.6M | 93.3K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.77% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | $10.60 |
| Revenue Next Year | $22.86 | $10.94 |
| P/E Ratio | $633.00 | ★ $22.68 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $44.94 |
| 52 Week High | $10.08 | $62.18 |
Technical Indicators
Market Signals| Indicator | XERS | MSEX |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 54.25 |
| Support Level | $5.81 | $51.83 |
| Resistance Level | $6.41 | $54.83 |
| Average True Range (ATR) | 0.27 | 1.09 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 40.48 | 81.75 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.